Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05870202 · ClinicalTrials.gov registry record
Treatment Burden Screening Questionnaire Pilot Study
A clinical trial of Type 2 Diabetes, sponsored by University of Minnesota.
- Completed
- Registry status
- 64
- Enrollment target
- 2
- Study locations
NCT05870202: Completed study of Type 2 Diabetes, sponsored by University of Minnesota.
NCT05870202 is a study of Type 2 Diabetes that has completed, run by University of Minnesota. The registered enrollment target is 64 participants, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05870202, a study of Type 2 Diabetes, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- 64 participants
- Enrollment target
- 2
- Study locations
Study Summary
The main objective of this study is to develop and evaluate a clinic-based pilot intervention to optimize patient-centered diabetes care for low income patients at risk for low quality diabetes care and poor outcomes.
Primary Outcome
Patients' willingness to participate in the study as assessed by: 1\) percentage of approached and eligible patients who consent to enroll in the study, 2) percentage of participants who completed the study procedures including baseline survey data collection, 3) use of the screening tool and completion of the post-intervention visit survey 4) time (days) to recruit 50 subjects across 2 clinic sites.
Conditions Studied
Interventions
- OTHER screening tool
Study Locations (2)
Minnesota
- Community University Health Center - Minneapolis
- Hennepin Health Care - Whittier Clinic - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2023-03-07 |
| Est. Completion | 2025-04-01 |
What the finished NCT05870202 record still lists
NCT05870202 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which screening tool is the first listed.
NCT05870202 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT05870202 about?
NCT05870202 is a clinical study titled "Treatment Burden Screening Questionnaire Pilot Study". The main objective of this study is to develop and evaluate a clinic-based pilot intervention to optimize patient-centered diabetes care for low income patients at risk for low quality diabetes care and poor outcomes.
What is the current status of trial NCT05870202?
This trial is currently completed. The enrollment target is 64 participants. The study started on 2023-03-07. Estimated completion is 2025-04-01.
What conditions does trial NCT05870202 study?
This clinical trial studies the following conditions: Type 2 Diabetes.
What interventions are being tested in trial NCT05870202?
The interventions under investigation include: screening tool (OTHER).
Who is sponsoring clinical trial NCT05870202?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05870202 being conducted?
This trial has 2 study locations across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05870202's enrollment target sits among peer trials
64 190th of 327 higher than 137 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Enhancing Telemedicine for T2D
RECRUITING · NA
-
Sleep and Glycemic Control in Type 2 Diabetes Adolescents
RECRUITING · NA
-
Enhancing Preventative Health Behaviors Among Emergency Department Hyperglycemic Patients
RECRUITING · NA
-
Ultrasound Effects on Glycemic Control in T2DM
RECRUITING · NA
-
Mechanism of SGLT2 Inhibition in the Kidney
RECRUITING · Phase 4
-
Acute and Chronic Effects of Oral Ketones in Subjects With HFrEF and Diabetes
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI